LRMR
Larimar Therapeutics Inc

4,535
Mkt Cap
$368.89M
Volume
272,468.00
52W High
$9.50
52W Low
$1.61
PE Ratio
-2.76
LRMR Fundamentals
Price
$4.24
Prev Close
$4.31
Open
$4.24
50D MA
$4.16
Beta
1.30
Avg. Volume
3.27M
EPS (Annual)
-$1.32
P/B
2.30
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation LRMR
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from...
Business Wire·8d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·12d ago
News Placeholder
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights LRMR
The DJS Law Group announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (Larimar or the Company) (NASDAQ: LRMR) for violations of the securities laws...
Business Wire·15d ago
News Placeholder
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (Larimar or the Company) (NASDAQ...
Business Wire·15d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·22d ago
News Placeholder
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study
The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia.
Stocktwits·1mo ago
News Placeholder
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Zacks·4mo ago
News Placeholder
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Zacks·4mo ago
News Placeholder
Buy Rating for Larimar Therapeutics Backed by Promising Gene Therapy Advances for Friedreich's Ataxia
Larimar Therapeutics (LRMR Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville...
TipRanks Financial Blog·1y ago

Latest LRMR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.